Study: Macrolide antibiotics may benefit non-CF bronchiectasis patients

Azithromycin and erythromycin significantly decreased the number of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis, but long-term use increased resistance to the drugs, according to two studies in the Journal of the American Medical Association. Azithromycin and erythromycin enhanced lung function, while azithromycin significantly improved quality of life.

View Full Article in:

PhysiciansBriefing.com · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY